Celdara Medical, LLC announced today that it has received a $2.1M SBIR Phase II award from the National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI). This award will support the preclinical development of Celdara Medical’s dendritic cell targeted therapy for myocardial infarction-induced ischemia-reperfusion injury. “Myocardial infarction is […]
Celdara Medical, LLC Receives $2.1M SBIR Award from the National Heart, Lung, and Blood Institute
Continue Reading